Medical Oncology Data by Tumor Type for Pharma Sales
Most modern oncology drugs are tumor-specific. Targeting 'oncologists' broadly wastes 70-90% of outreach.
2026-04-09
Major Tumor Segments
Breast oncology
Largest solid tumor. Sub-segment by molecular subtype: HER2-positive, HR-positive, triple-negative. Each subtype requires different drugs.
Thoracic oncology
Immunotherapy and mutation-specific targeted therapy (EGFR, ALK, KRAS G12C). Thoracic specialists at academic centers treat biomarker-driven cases.
GI oncology
Colorectal, pancreatic, hepatocellular. Distinct treatment patterns per tumor type. Colorectal has targeted therapy; pancreatic does not.
Hematologic oncology
Leukemia, lymphoma, myeloma. Highest per-patient drug costs (CAR-T $400K+, bispecifics). Academic centers with CAR-T programs are primary targets.
GU oncology
Prostate (androgen receptor inhibitors, PARP), bladder (immunotherapy), kidney (TKI/immunotherapy combos). Growing pharma spend.
Frequently Asked Questions
Why segment oncologists by tumor type?
Modern drugs are tumor-specific. Targeting broadly wastes outreach on providers who don't have the relevant patient population.
How do you determine tumor-type focus?
Layer ABIM certification, publications, clinical trial PI records, NCCN panel membership, and practice website analysis.
Which segment has highest pharma spend?
Hematologic malignancies (CAR-T, bispecifics) have highest per-patient cost. Breast cancer has highest total spend by volume.
Sources and References
Related Resources
Get the Provider Data You Need
Tell us what you're looking for. We'll build a custom list matched to your target market.
Trusted by healthcare sales teams, medical device companies, and health IT vendors across the US.